Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypereosinophilic Syndrome - Overview
Hypereosinophilic Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypereosinophilic Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
Hypereosinophilic Syndrome - Drug Profiles
Hypereosinophilic Syndrome - Dormant Projects
Hypereosinophilic Syndrome - Product Development Milestones
Featured News & Press Releases
Nov 17, 2021: European Commission approves Nucala (mepolizumab) in three additiol eosinophil-driven diseases
Sep 17, 2021: GSK receives CHMP positive opinions recommending approval of Nucala (mepolizumab) in three additiol eosinophil-driven diseases
Sep 15, 2021: NUCALA (mepolizumab) approved in Cada as the first and only biologic treatment for adults with hypereosinophilic syndrome
Jan 15, 2021: Knopp Biosciences reports positive trial results of oral asthma drug
Oct 29, 2020: GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additiol eosinophil-driven diseases
Sep 28, 2020: GSK’s Nucala receives FDA approval to treat HES
Sep 16, 2020: Knopp Biosciences completes enrollment in phase 2 trial of oral dexpramipexole in eosinophilic asthma
May 27, 2020: FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
Dec 03, 2019: Knopp to start trial enrollment of oral dexpramipexole in H1 2020
Nov 14, 2019: GSK reports positive data for Nucala in late-stage HES trial
Aug 19, 2019: Knopp begins study of dexpramipexole in eosinophilic asthma patients
Jul 09, 2019: Knopp Biosciences to present clinical data for Dexpramipexole at 11th Biennial Symposium of the Intertiol Eosinophil Society
Apr 24, 2019: Knopp Biosciences receives FDA Orphan Drug Desigtion for Dexpramipexole for treatment of Hypereosinophilic Syndrome
Apr 05, 2019: Study finds AstraZeneca’s asthma drug could treat immune disorder
Apr 03, 2019: FDA-approved drug effectively treats rare chronic immune disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Hypereosinophilic Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Hypereosinophilic Syndrome, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hypereosinophilic Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
Hypereosinophilic Syndrome - Pipeline by Areteia Therapeutics Inc, 2022
Hypereosinophilic Syndrome - Pipeline by GSK plc, 2022
Hypereosinophilic Syndrome - Pipeline by Incyte Corp, 2022
Hypereosinophilic Syndrome - Pipeline by Kyowa Kirin Co Ltd, 2022
Hypereosinophilic Syndrome - Pipeline by Nexeos Bio, 2022
Hypereosinophilic Syndrome - Dormant Projects, 2022